Instrument Inactif

Autres langues Allos Therapeutics, Inc.

Actions

US0197771019

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

Autres langues

05/09/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics
29/08/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012
17/08/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
04/08/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
20/07/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
07/07/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
22/06/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
08/06/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
25/05/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
10/05/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics
02/05/12	Allos Therapeutics, Inc. : Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.
20/04/12	Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN(R) in Europe
20/04/12	Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe
16/04/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
05/04/12	Allos Therapeutics, Inc. : (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals
05/04/12	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
06/03/12	Allos Therapeutics, Inc. : Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
21/02/12	Allos Therapeutics, Inc. : Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012
30/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN(R) and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
30/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN(R) in PTCL at the European Medicines Agency
30/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency
30/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN® and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
20/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
10/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities
10/01/12	Allos Therapeutics, Inc. : Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities